Gary Sender
CIK 1659085 · Chief Financial Officer · last filed 2026-05-18
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$264.8K
Companies
4
Total Filings
43
Lifetime Open-Market Net
-$1.87M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| HRMY | Director | — | $34.46 | — | $0 | 7 | 2026-05-18 |
| IBIO | Director | 9,191 | $1.69 | $15.5K | $25.0K | 5 | 2025-11-24 |
| SDGR | Director | 17,247 | $14.45 | $249.2K | -$1.91M | 7 | 2025-06-20 |
| Nabriva Therapeutics plc (NBRV) Delisted | Chief Financial Officer | 20,472 | $1.42 | $29.1K | $18.5K | 23 | 2021-03-02 |
Recent Filings · Page 5 of 5
43 filingsForm 4 transactions across all companies, newest first.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2017-09-26 | Nabriva Therapeutics plc (NBRV) Delisted | Buy (P) | +2,000 | $16.4K | EDGAR |
| 2017-06-28 | — | Other (J) | +2,200 | $0 | |
| 2017-02-09 | Nabriva Therapeutics plc (NBRV) Delisted | Grant (A) | — | $0 | EDGAR |
Showing 41–43 of 43
Prev
Page 5 of 5
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.